BridgeBio Oncology Therapeutics (BBOT) Accumulated Expenses (2023 - 2026)

BridgeBio Oncology Therapeutics has reported Accumulated Expenses for 4 years, with the latest figure at $2.0 million in Q1 2026.

• Quarterly Accumulated Expenses rose 13.14% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 13.14% YoY) and the FY2025 annual result came in at $5.7 million, up 50.38% from the prior year.
• Accumulated Expenses retreated to $2.0 million in Q1 2026 per BBOT's latest filing, from $5.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $5.7 million in Q4 2025 and troughed at $15000.0 in Q4 2023.
• A 4-year average of $2.0 million and a median of $1.8 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Accumulated Expenses surged 25373.33% in 2024, then increased 13.14% in 2026.
• Over 4 years, Accumulated Expenses stood at $15000.0 in 2023, then soared by 25373.33% to $3.8 million in 2024, then surged by 50.38% to $5.7 million in 2025, then slumped by 64.88% to $2.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.0 million, $5.7 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.